LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome) | NCT01464086 | Trialant
CompletedInterventionalPhase 3Updated Feb 25, 2021
LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
ClinicalTrials.gov ID
NCT01464086
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand ParisOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
107Actual
Last Update Posted
Feb 25, 2021Actual
Start Date
Oct 27, 2011Actual
Primary Completion Date
Mar 31, 2017Actual
Completion Date
Oct 9, 2017Actual
Brief Summary
The purpose of this study is to compare the diagnostic efficacy of two follow-up schedules for the early detection of cancers in the population under study on cancer incidence at 3 years.